Air China Ltd
Change company Symbol lookup
Select an option...
AICAF Air China Ltd
XOM Exxon Mobil Corp
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc
NLY Annaly Capital Management Inc
APM Aptorum Group Ltd
T AT&T Inc
ABBV Abbvie Inc

Based in China
Company profile

Air China Limited is a China-based company principally engaged in the provision of air passenger transportation, freight transportation, postal transportation and maintenance services in Mainland China, Hong Kong, Macau and foreign regions. The Company is also engaged in domestic and international business aviation businesses, plane business, aircraft maintenance, airlines business agents, ground and air express services related to main businesses, duty free on boards, retail business on boards and aviation accident insurance sales agents business.

Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

Today's volume of 0 shares is on pace to be much lighter than AICAF's 10-day average volume of 5,932 shares.


AHF: 'Gilead: We Told You So on COVID Drug Pricing!'

7:27 pm ET August 4, 2020 (BusinessWire) Print

--In May, AIDS Healthcare Foundation demanded that the drug company price remdesivir, the newly approved drug for treating COVID-19--which Gilead had developed years earlier with $70M in government funding as a possible Ebola treatment--at one dollar per day per patient

AIDS Healthcare Foundation (AHF) today praised the 34 state attorneys general for taking action to bring down the cost and increase the supply of Gilead Sciences' remdesivir, the only approved treatment for COVID-19, the novel coronavirus.

"The August 4 letter from the attorneys general basically echoes and implements what AHF has been saying since as far back as March 30, that since taxpayers paid for the research and development--and are now paying for the production of this essential medicine--the price should be reasonable," said Tom Myers, general counsel and chief of public affairs for AHF.

In May, Gilead, which developed the drug years earlier (with as much as $70 million in government research and development funding) as a possible Ebola treatment, announced that it would set the price for remdesivir between $2,300 and $3,100 per patient for a five-day course of treatment. AHF issued a statement demanding that Gilead price the drug at no more than one dollar per day.

AHF's dollar per dose demand is based on a University of Liverpool research study, "Minimum costs to manufacture new treatments for COVID-19," that allows for recovery of the cost of manufacturing plus a reasonable profit.

"We applaud these state elected officials for standing up to Gilead's greed and thank them for taking this action," added John Hassell, national advocacy director for AHF.

About AIDS Healthcare Foundation (AHF)

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.4 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website:, find us on Facebook: and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.

View source version on

SOURCE: AIDS Healthcare Foundation">


Ged Kenslea, Senior Director, Communications, AHF
+1.323.791.5526 [cell]
+.323.308.1833 [work] 

John Hassell, National Director of Advocacy, AHF
+1.202.774.4854 [cell]
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.